Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Karus Therapeutics Appoints Penelope Ward as CMO

Published: Tuesday, November 12, 2013
Last Updated: Tuesday, November 12, 2013
Bookmark and Share
Dr Ward will drive Company’s HDAC6 and PI3K inhibitor programmes.

Karus Therapeutics has announced that Penelope Ward has joined the Company in the role of Chief Medical Officer.

Her appointment strengthens the Company’s expansion which recently saw the formation of a Scientific Advisory Board, appointment of additional R&D personnel and a move to a world-class biotech hub near Oxford.

Dr Ward, who took up her new position in October, is an experienced pharmaceutical physician with previous senior management roles at Pharmacia and Upjohn (Pfizer), UCB and Roche, and was previously Chief Medical Officer of Novimmune SA.

Her expertise in designing and implementing clinical development strategies will be important for the role at Karus where she will take responsibility for driving the Company’s HDAC6 and PI3K inhibitor programmes through early human efficacy trials in inflammation and cancer.

In addition, Dr Ward brings with her broad capabilities in commercial licensing negotiations, having previously supported deals for novel research targets to full development candidates.

Along with a solid track record in obtaining regulatory approval, Dr Ward is well placed to assist the Company in future strategic decision making.

Commenting on Dr Ward’s appointment, Dr Simon Kerry, Chief Executive of Karus, said: “With the wealth of expertise that Penny brings to the position, we are confident she will be an asset to the team and look forward to working together to further develop and strengthen our proprietary programmes to treat inflammation and cancer.”

Dr Ward, Chief Medical Officer, added: “Karus is at a very exciting stage in its development, being well funded by supportive investors and with a great team. I look forward to working with the Board, management and scientists to progress the Company’s assets and realize the potential of its technology.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Karus Therapeutics Appoints Scientific Advisory Board
Company announces move to new Oxford facilities.
Tuesday, April 09, 2013
Karus Secures Series B Financing from a Syndicate of Leading VC Investors
New investment to support the development of Karus’s innovative PI3K and HDAC6 programmes through early human trials.
Thursday, January 17, 2013
Karus Therapeutics Announces Collaboration with Babraham Institute
Collaboration to explore PI3 kinase inhibitors in the treatment of inflammatory diseases.
Tuesday, December 18, 2012
Karus Commences Preclinical Development of Novel Immune and Inflammation Programmes
The Company aims to initiate clinical trials for both programmes in 2011.
Wednesday, November 03, 2010
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
TOPLESS Plants Provide Clues to Human Molecular Interactions
Scientists at Van Andel Research Institute have revealed an important molecular mechanism in plants that has significant similarities to certain signaling mechanisms in humans, which are closely linked to early embryonic development and to diseases such as cancer.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Study Finds Non-Genetic Cancer Mechanism
Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Find U.S. Breast Milk is Glyphosate Free
Washington State University scientists have found that glyphosate, the main ingredient in the herbicide Roundup, does not accumulate in mother’s breast milk.
Peering into the Vapors
Research suggests that e-cigarettes are much less harmful than previous studies have indicated.
New Technique for Mining Health-conferring Soy Compounds
A new procedure devised by U.S. Department of Agriculture (USDA) scientists to extract lunasin from soybean seeds could expedite further studies of this peptide for its cancer-fighting potential and other health benefits.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!